GNRSW: AI 评分 43/100 — AI 分析 (4月 2026)

Greenrose Holding Company Inc. focuses on the production and sale of cannabis products, including cultivation, processing, and packaging of medical cannabis and derivative products. The company operates in the evolving cannabis industry, navigating regulatory landscapes and market competition.

Key Facts: AI Score: 43/100 Sector: Healthcare

公司概况

概要：

Greenrose Holding Company Inc. cultivates, processes, and packages medical cannabis and derivative products, positioning itself within the specialty and generic drug manufacturing segment of the healthcare sector. Founded in 2014, the company aims to serve the growing demand for medical cannabis products amidst evolving regulations and market dynamics.

GNRSW是做什么的？

Greenrose Holding Company Inc., established in 2014 and headquartered in Amityville, New York, operates in the cannabis industry through its subsidiaries. The company focuses on the production and sale of cannabis products, specifically engaging in the cultivation, processing, and packaging of medical cannabis and derivative products. This includes a range of cannabis-based medications and related items aimed at addressing various medical needs. The company's business model centers around vertically integrated operations, controlling the process from cultivation to final product distribution. This allows Greenrose to maintain quality control and potentially capture higher margins throughout the value chain. Greenrose's products are targeted towards patients and consumers in jurisdictions where medical cannabis is legal. The company navigates a complex regulatory environment, adhering to state and local laws governing cannabis production and sales. Greenrose aims to expand its market presence and product offerings, capitalizing on the increasing acceptance and legalization of cannabis for medical purposes. The company faces competition from other cannabis producers and pharmaceutical companies exploring cannabis-based therapies. Greenrose’s success depends on its ability to efficiently manage its operations, innovate in product development, and adapt to the changing regulatory landscape.

GNRSW的投资论点是什么？

Greenrose Holding Company Inc. presents a speculative investment opportunity within the evolving cannabis industry. With a market capitalization of $0.00B and a high beta of 3309.14, the stock demonstrates significant volatility. The company's reported profit margin of 70.6% and gross margin of 59.1% suggest potential profitability, but these figures need to be validated with consistent performance over time. Growth catalysts include the expansion of legal cannabis markets and the development of new cannabis-based products. However, the company faces risks related to regulatory uncertainty, competition, and the challenges of operating in the OTC market. Investors should carefully assess the company's financial stability, operational efficiency, and ability to navigate the complex regulatory landscape before considering an investment. The lack of a dividend yield reflects a focus on reinvesting earnings for growth.

GNRSW在哪个行业运营？

Greenrose Holding Company Inc. operates within the rapidly evolving cannabis industry, which is experiencing significant growth due to increasing legalization and acceptance of cannabis for medical and recreational purposes. The market is characterized by intense competition, with numerous companies vying for market share. Greenrose competes with both established cannabis producers and pharmaceutical companies exploring cannabis-based therapies. The industry is subject to complex and changing regulations, which pose challenges and opportunities for companies like Greenrose. The global legal cannabis market is projected to reach billions of dollars in the coming years, presenting significant growth potential for companies that can navigate the regulatory landscape and establish a strong market position.

Drug Manufacturers - Specialty & Generic

Healthcare

GNRSW有哪些增长机遇？

Expansion into New Markets: As more states and countries legalize cannabis for medical or recreational use, Greenrose has the opportunity to expand its geographic reach. This includes establishing cultivation and distribution facilities in new markets, either organically or through acquisitions. The global legal cannabis market is projected to reach $42.7 billion by 2027, presenting a significant opportunity for Greenrose to increase its revenue and market share. Timeline: Ongoing, dependent on regulatory changes and market entry strategies.
Product Innovation and Development: Greenrose can invest in research and development to create new and innovative cannabis-based products, such as novel formulations, delivery methods, or therapeutic applications. This can help the company differentiate itself from competitors and capture a larger share of the market. The market for cannabis-infused products is growing rapidly, with consumers seeking new and convenient ways to consume cannabis. Timeline: Ongoing, with new products potentially launching within the next 1-3 years.
Strategic Partnerships and Acquisitions: Greenrose can pursue strategic partnerships or acquisitions to expand its capabilities, access new markets, or consolidate its position in existing markets. This could include partnering with other cannabis companies, pharmaceutical companies, or research institutions. The cannabis industry is undergoing consolidation, with larger companies acquiring smaller players to gain scale and market share. Timeline: Ongoing, with potential deals occurring within the next 1-2 years.
Development of Branded Products: Creating strong, recognizable brands can help Greenrose build customer loyalty and differentiate itself from competitors. This includes investing in marketing, advertising, and packaging to create a consistent brand image. The cannabis market is becoming increasingly brand-conscious, with consumers seeking out trusted and reputable brands. Timeline: Ongoing, with brand development efforts continuing over the next several years.
Focus on Medical Cannabis: Greenrose can focus on the medical cannabis market, which offers higher margins and greater regulatory certainty compared to the recreational market. This includes developing cannabis-based therapies for specific medical conditions and working with healthcare professionals to promote their use. The medical cannabis market is expected to continue to grow as more research supports the therapeutic benefits of cannabis. Timeline: Ongoing, with a focus on clinical trials and regulatory approvals over the next 3-5 years.

Profit Margin of 70.6% indicates strong potential profitability, though it needs to be sustained over time.
Gross Margin of 59.1% suggests efficient cost management in the production and sale of cannabis products.
Beta of 3309.14 indicates extremely high volatility compared to the broader market.
Market Cap of $0.00B reflects the company's small size and potential for growth or instability.
The company does not offer a dividend, suggesting a focus on reinvesting earnings for future expansion.

GNRSW提供哪些产品和服务？

Cultivates medical cannabis.
Processes raw cannabis into usable forms.
Packages cannabis products for distribution.
Sells medical cannabis products to patients and consumers.
Develops derivative cannabis products.
Operates in jurisdictions where medical cannabis is legal.

GNRSW如何赚钱？

Vertically integrated operations from cultivation to distribution.
Focus on medical cannabis products.
Sales through dispensaries and other retail channels.
Revenue generated from the sale of cannabis products.

Patients with medical conditions that qualify for medical cannabis use.
Consumers in jurisdictions where recreational cannabis is legal.
Dispensaries and retail stores that sell cannabis products.
Healthcare professionals who recommend medical cannabis to their patients.

Vertically integrated operations provide cost control and quality assurance.
Proprietary cultivation and processing techniques.
Established relationships with dispensaries and retailers.
Brand recognition in specific markets.

什么因素可能推动GNRSW股价上涨？

Upcoming: Potential changes in cannabis regulations at the state or federal level could create new market opportunities.
Ongoing: Expansion of the company's product line to include new cannabis-based therapies.
Ongoing: Strategic partnerships with other companies in the cannabis industry to expand market reach.
Upcoming: Positive results from clinical trials of the company's cannabis-based products.
Ongoing: Increasing acceptance and legalization of cannabis for medical purposes.

GNRSW的主要风险是什么？

Potential: Regulatory uncertainty and changes in cannabis laws could negatively impact the company's operations.
Ongoing: Intense competition from other cannabis producers could erode market share and profitability.
Potential: Price volatility in the cannabis market could impact the company's revenue and earnings.
Ongoing: Challenges of operating in the OTC market, including limited liquidity and disclosure requirements.
Potential: Negative publicity or reputational damage could harm the company's brand image.

GNRSW的核心优势是什么？

Vertically integrated operations.
High profit margin (70.6%).
Established presence in specific markets.
Focus on medical cannabis.

GNRSW的劣势是什么？

OTC listing indicates higher risk and lower liquidity.
High beta (3309.14) indicates extreme volatility.
Small market capitalization ($0.00B).
Limited financial information available.

GNRSW有哪些机遇？

Expansion into new legal cannabis markets.
Development of new cannabis-based products.
Strategic partnerships and acquisitions.
Growing demand for medical cannabis.

GNRSW面临哪些威胁？

Regulatory uncertainty and changes in cannabis laws.
Intense competition from other cannabis producers.
Price volatility in the cannabis market.
Challenges of operating in the OTC market.

GNRSW的竞争对手是谁？

BevCanna Enterprises Inc — Focuses on cannabis-infused beverages. — (BLEVF)
Encore Plus Financial Corp. — Unknown differentiation due to limited information. — (EPRSQ)
Grown Up Group Inc. — Unknown differentiation due to limited information. — (GWHP)
Inter-Pacific Resources Inc — Unknown differentiation due to limited information. — (INTP)
Medltoons Inc. — Unknown differentiation due to limited information. — (MLTO)

Key Metrics

MoonshotScore: 43/100

Company Profile

CEO: Nicole Conboy
Employees: 91
Founded: 2020

AI Insight

AI analysis pending for GNRSW

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Greenrose Acquisition Corp. do?

Greenrose Holding Company Inc., through its subsidiaries, cultivates, processes, and sells cannabis products, primarily focusing on medical cannabis and derivative products. The company operates in the healthcare sector, specifically within the specialty and generic drug manufacturing segment. Its core activities include cultivating cannabis plants, processing them into various forms suitable for medical use, packaging the products, and distributing them through legal channels. Greenrose aims to capitalize on the growing demand for medical cannabis while adhering to regulatory requirements.

What do analysts say about GNRSW stock?

There is no available analyst consensus on GNRSW stock. Given its OTC listing and limited information, comprehensive analyst coverage is unlikely. Key valuation metrics such as price targets and ratings are not readily available. Investors should rely on their own due diligence and risk assessment when considering an investment in GNRSW. The company's growth potential is tied to the expansion of the legal cannabis market, but significant risks remain due to regulatory uncertainty and competition.

What are the main risks for GNRSW?

The primary risks for Greenrose Holding Company Inc. include regulatory uncertainty in the cannabis industry, intense competition from other cannabis producers, and the challenges of operating in the OTC market. Changes in cannabis laws at the state or federal level could significantly impact the company's operations and profitability. The OTC listing indicates higher risk and lower liquidity compared to major exchanges. Investors should carefully assess these risks before investing in GNRSW.